Top Premarket Gainers-February 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Top Premarket Gainers

Apr 19, 2024 5:06 AM

07:43 AM EDT, 04/19/2024 (MT Newswires) -- Zhongchao ( ZCMD ) shares doubled Friday premarket, adding to an increase from the previous session.

Redwoods Acquisition Corp. ( RWOD ) shares surged 72% after Thursday's 3.2% drop.

Hub Cyber Security ( HUBC ) shares increased 14% following a 4.4% drop in the previous session.

Top Wealth Group Holding ( TWG ) shares rose 10%, a day after the company closed its initial public offering.

Previous page： --GXO Logistics Shares Rise Pre-Bell After Bloomberg Reports Company Exploring Sale Next page： US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--GXO Logistics Shares Rise Pre-Bell After Bloomberg Reports Company Exploring Sale

Oct 10, 2024

07:58 AM EDT, 10/10/2024 (MT Newswires) -- Price: 56.06, Change: +5.16, Percent Change: +10.14 ...

US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

Oct 10, 2024

NEW YORK, Oct 10 (Reuters) - U.S. Senator Elizabeth Warren has asked antitrust regulators to closely scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent ( CTLT ), saying it may give the pharmaceutical company an unlawful advantage in weight loss and obesity drugs. Novo Holdings, the investment firm that has a...

Immatics Launches $150 Million Public Offering of Ordinary Shares

Oct 10, 2024

07:58 AM EDT, 10/10/2024 (MT Newswires) -- Immatics ( IMTX ) said Thursday that it has launched a $150 million underwritten public offering of its ordinary shares. The company said there is no guarantee as to when or if the offering will be completed, or as to the actual size and terms of the offering, as these are contingent on...

Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell

Oct 10, 2024

07:56 AM EDT, 10/10/2024 (MT Newswires) -- Tempest Therapeutics ( TPST ) said Thursday it is working with Roche to advance amezalpat into a phase 3 trial in combination with atezolizumab and bavacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma. As part of the agreement, Roche will provide atezolizumab worldwide, while Tempest will sponsor and lead the...